Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 9/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.41 |
| ▸ | CYBB | P04839 | 1/20 | 0.39 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25046541 | 0.87 | P2RX7 (0.46) | DRD2DRD4DRD3NCF1DGAT1 | |
| SCHEMBL18850695 | 0.87 | DGAT1 (0.47) | DRD2DRD4DRD3NCF1DGAT1 | |
| SCHEMBL25138066 | 0.87 | DGAT1 (0.47) | DRD2DRD4DRD3NCF1DGAT1 | |
| SCHEMBL20691581 | 0.86 | GBA1 (0.43) | DRD2DRD4DRD3NCF1CYBB | |
| SCHEMBL23267583 | 0.85 | DRD2 (0.40) | DRD2DRD4DRD3NCF1CYBB | |
| SCHEMBL20805924 | 0.83 | P2RX7 (0.41) | DGAT1P2RX7HSP90AB1NOTUM | |
| SCHEMBL18457287 | 0.83 | MAPT (0.44) | DRD2DRD4DRD3NCF1DGAT1 | |
| SCHEMBL23176012 | 0.83 | DGAT1 (0.44) | DGAT1HSP90AB1NOTUM | |
| SCHEMBL22787028 | 0.82 | DRD2 (0.39) | DRD2DRD4DRD3NCF1CYBB | |
| SCHEMBL19775889 | 0.82 | CYP19A1 (0.50) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | DRD2 4604/4885DRD4 4799/4885DRD3 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.